Investor Relations

Company Overview

We are a biotechnology company dedicated to developing treatments for certain medical conditions. Currently, we have two programs focused on kidney disease that we believe have the potential to offer medical benefit. As we grow the Company and build our team, we intend to focus on identifying medical conditions within and outside of kidney disease. Our current development programs are focused on the development of two novel therapies: Oxylanthanum Carbonate (OLC), for the treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494 for the treatment of acute kidney injury.